Ning Qin

[Expert Profile] Ning Qin, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in infectious diseases in China, working in the Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. She has long been dedicated to clinical diagnosis, treatment, and scientific research of refractory hepatitis B, severe hepatitis, and difficult febrile infections, and is an important leading figure in infectious diseases in China.

[Education & Career] Professor Ning Qin graduated from Tongji Medical University, completed systematic clinical training at Tongji Hospital, and further studied at famous international infectious disease centers. She has long served as Director of the Department of Infectious Diseases at Tongji Hospital, holding important academic positions including Vice Chair of the Infectious Diseases Branch of the Chinese Medical Association. She has presided over key grants from the National Natural Science Foundation of China and the National Key R&D Program, and has accumulated profound academic achievements in the fields of liver disease and infectious diseases.

[Areas of Expertise] Professor Ning specializes in standardized antiviral treatment of chronic hepatitis B, comprehensive treatment of severe hepatitis and liver failure, and differential diagnosis of difficult fever and infectious diseases. She has extensive experience in individualized selection of nucleoside analogs and interferons, hepatitis B virus resistance management, and comprehensive supportive treatment of severe liver disease. She excels at managing difficult cases of "poor antiviral response and repeatedly abnormal liver function" in refractory hepatitis B and fever of unknown origin, helping numerous patients control the virus and avoid liver failure.

[Academic Achievements & Industry Contributions] Professor Ning has led a series of clinical studies on optimized hepatitis B treatment and severe liver disease management, systematically evaluating the real-world effectiveness of hepatitis B antiviral therapy and severe hepatitis treatment strategies in Chinese populations, with findings published in authoritative domestic and international journals. She has participated in the development of Chinese hepatitis B prevention and treatment and liver failure diagnosis and treatment guidelines, actively promoted hepatitis B mother-to-child transmission blockade, standardized antiviral therapy, and the construction of a multidisciplinary severe liver disease treatment system, making important contributions to reducing hepatitis B-related liver disease mortality in China.

[Clinical Practice & Outstanding Contributions] For decades on the front lines of infectious disease and liver disease clinical work, Professor Ning has treated tens of thousands of patients with hepatitis B, severe hepatitis, and various infectious diseases, successfully managing numerous critical liver failure patients. She is serious and responsible with patients, dedicated, and has repeatedly participated in major infectious disease prevention and control efforts. She has been repeatedly recognized as an outstanding discipline leader, trained a large number of infectious disease professionals, and is deeply trusted by patients and respected by peers alike.

[Honors & Reputation] Professor Ning Qin serves as Director of the Department of Infectious Diseases at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology and Vice Chair of the Infectious Diseases Branch of the Chinese Medical Association, among other academic positions. She has presided over national-level projects including key grants from the National Natural Science Foundation of China and the National Key R&D Program, and is an authoritative expert in the field of infectious diseases in China. She has profound expertise in the diagnosis and treatment of refractory hepatitis B, severe hepatitis, and difficult febrile infections. She has led research on optimized hepatitis B treatment and severe liver disease management, promoted the construction of hepatitis B mother-to-child transmission blockade and standardized antiviral therapy systems, participated in the development of multiple liver disease and infectious disease diagnosis and treatment guidelines, and has research findings published in authoritative domestic and international journals. For decades on the clinical front lines, she has successfully treated numerous severe hepatitis patients, and is deeply trusted by patients and respected by peers alike.